Showing 2941-2950 of 4802 results for "".
Cutaneous T-Cell Lymphoma: Mogamulizumab as a Novel Treatment for Refractory Mycosis Fungoides and Sezary Syndrome
https://practicaldermatology.com/youngmd-connect/resident-resource-center/Cutaneous-T-Cell-Lymphoma-Mogamulizumab-as-a-Novel-Treatment-for-Refractory-Mycosis-Fungoides-and-Sezary-Syndrome/23409/An overview of the diagnosis and prognosis of CTCL.A User's Guide to the Field of Biologic Therapies
https://practicaldermatology.com/topics/psoriasis/PD0709_01-php/22796/All the facts you need to know about available biologic therapies, assembled in one place.Sunscreen Ratings, Restylane Lyft for Hands, NPF, SCF News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-ratings-restylane-lyft-for-hands-npf-scf-news/18305/Both Consumer Reports and the Environmental Working Group have issued sunscreen rankings, and while some products shine, many products may underperform. FDA issued warnings to several companies illegally marketing dietary supplements that make unproven drug claims about protecting consumers from sunAD Impact, Allofill Comes to Market, GPA Launches
https://practicaldermatology.com/topics/psoriasis/dermwiretv-ad-impact-allofill-comes-to-market-gpa-launches/18567/From sleep disruptions or negative impact on the ability to work to feelings of depression and anxiety, atopic dermatitis can have significant effects on adults, new research suggests. In fact, more than half of respondents to a Harris Poll say that AD has negatively impacted their daily lives. DoriKamedis Botanically-based Regimen for Dandruff
https://practicaldermatology.com/topics/general-topics/kamedis-botanically-based-regimen-for-dandruff/18579/Kamedis brings innovation to the treatment of seborrheic dermatitis (SD, also called dandruff) with a botanically-based 2-step hair care system. The two-step Kamedis system for seborrheic dermatitis consists of SEBOMedis Anti-Dandruff Shampoo and Scalp Lotion. Botanical ingredients include indigo (IDermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveAltreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobExploring Patient-Reported Outcomes Measures in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/exploring-patient-reported-outcomes-measures-in-atopic-dermatitis/23886/Patient-reported outcomes may solve some of the challenges with measuring the physical and psychosocial manifestations.Managing Diaper Dermatitis
https://practicaldermatology.com/topics/pediatric/managing-diaper-dermatitis/20357/First-line treatment tips and a review of when to assess for an alternate diagnosis.What If It’s Not Atopic Dermatitis?
https://practicaldermatology.com/topics/infections-infectious-disease/what-if-its-not-atopic-dermatitis/23812/A photo-assisted guide to differential diagnosis.